Allogene Therapeutics, Inc. (ALLO)
$
1.44
-0.08 (-5.56%)
Key metrics
Financial statements
Free cash flow per share
-0.7160
Market cap
323.6 Million
Price to sales ratio
0
Debt to equity
0.2446
Current ratio
8.1902
Income quality
0.7469
Average inventory
0
ROE
-0.5779
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. The company reported depreciation and amortization expenses of $13,639,000.00 reflecting the wear and tear of its assets, which is a vital element in assessing its financial health. The weighted average number of shares outstanding is 194,812,000.00 highlighting the company's shareholder base and its appeal to investors. Allogene’s operating expenses amount to $273,221,000.00 encompassing various operational costs incurred during its innovative development processes. The cost of revenue for the company is $0.00 showcasing its production and operational expenses, which are crucial to its overall profitability. Consequently, the gross profit stands at $22,000.00 highlighting the company's financial performance from core operations as it champions the fight against cancer. The company develops, manufactures, and commercializes products like UCART19 for R/R CD19 positive B-cell ALL, and several other promising candidates for various cancers, thus forming a diverse product portfolio that underscores its dedication to improving patient outcomes. The stock is affordable at $1.16 suitable for budget-conscious investors, making it accessible to a wider range of potential shareholders. Additionally, the stock has a high average trading volume of 2,706,330.00 indicating strong liquidity, which is often a desirable trait for active traders. With a market capitalization of $323,611,407.00 the company is classified as a small-cap player, positioning it uniquely within the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth, which enhances its reputation and attractiveness as an investment option. Through strategic collaborations and groundbreaking research, Allogene Therapeutics, Inc. continues to be a forward-thinking entity in the competitive field of immuno-oncology.
Is Allogene Therapeutics, Inc. (ALLO) a good investment?
Investing in Allogene Therapeutics, Inc. (ALLO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Allogene Therapeutics, Inc. (ALLO)'s stock forecast?
Analysts predict Allogene Therapeutics, Inc. stock to fluctuate between $0.86 (low) and $3.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Allogene Therapeutics, Inc.'s market capitalization?
As of 2025-12-04, Allogene Therapeutics, Inc.'s market cap is $323,611,407, based on 224,730,144 outstanding shares.
How does Allogene Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Allogene Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Allogene Therapeutics, Inc. (ALLO) stock?
To buy Allogene Therapeutics, Inc. (ALLO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALLO. Place an order (Market, Limit, etc.).
What is the best time to invest in Allogene Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Allogene Therapeutics, Inc. perform in the last earnings report?
Revenue: $22,000 | EPS: -$1.32 | Growth: -36.84%.
Where can I find Allogene Therapeutics, Inc.'s investor relations reports?
Visit https://www.allogene.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Allogene Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Allogene Therapeutics, Inc. stock?
All-time high: $27.86 (2021-09-23) | All-time low: $0.86 (2025-05-14).
What are the key trends affecting Allogene Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.
seekingalpha.com
Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility analysis in H1 2026, but must proceed without ALLO-647. ALLO-316 showed a 31% response rate in advanced RCC patients with CD70+ TPS ≥50%, but future studies will require this narrow focus.
zacks.com
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
seekingalpha.com
Allogene Therapeutics, Inc. ( ALLO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Geoffrey Parker - Executive VP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Corwin - William Blair & Company L.L.C.
businesswire.com
LINCOLN, Neb. & SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Calix, Inc. (NYSE: CALX) today announced that ALLO Communications has launched Smart Schools, an innovative program built on Calix SmartTown® for Education and fully integrated with the Calix Broadband Platform. Smart Schools will provide safe, secure community Wi-Fi for Lincoln Public School (LPS) students in grades 6-12 who opt into the program—promoting digital equity and extending learning beyond the classroom. Leveraging their Calix techno.
seekingalpha.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Citi's SMID Call Series 2025 October 2, 2025 1:00 PM EDT Company Participants Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Citigroup Inc., Research Division Good afternoon, and thank you for joining. I'm Sam Semenkow, one of the senior biotech analysts here at Citi, and it's my pleasure to be hosting Allogene's Executive Vice President and CMO, Zach Roberts, as a part of Citi's SMID Biotech C-suite virtual fireside chat series.
zacks.com
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
zacks.com
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September.
seekingalpha.com
I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; positive MRD data could significantly revalue the stock from current depressed levels.
See all news
